Postoperative Nausea And Vomiting (PONV) Treatment Industrial and Market studies - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2016 - 2020
Albany, New York, Jan 11,2017
"Postoperative
Nausea And Vomiting (PONV) Treatment Market - Global Industry
Analysis, Size, Share, Growth, Trends And Forecast 2016 - 2020"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
Description-
Postoperative
nausea and vomiting (PONV) is among the most common after surgery
adverse events, which occur during the first 24 hours to 48 hours
post surgery in patients. It has been observed that, on an average
20% to 30% of patients undergoing surgery suffer from vomiting and
nausea postoperatively. The incidence of PONV depends on variety of
factors, including type of surgery, gender and anesthetic drugs used.
Generally, the consequences of PONV are minor, but the impact on
medical resources and patient comfort can be significant.
At
present, the postoperative nausea and vomiting treatment market is
expected to grow at a significant rate due to the high incidence rate
of postoperative complications, which makes this industry a promising
market venture.
–
Some of the antiemetics commonly used for the management of PONV
are:
- Serotonin antagonists
- Ondansetron
- Granisetron
- Dolasetron
- Palonosetron
- Steroids
- Dexamethason
- Cholinergic antagonists
- Scopolamine
- Dopamine antagonists
- Butyrophenones
- Benzamides
- Phenothiazines
- Antihistamines
- Diphenhydramine
- Dimenhydrinate
From the geographical perspective, North America
and Europe are the largest markets for postoperative nausea and
vomiting treatment market due to the elevated number of surgical
procedures performed and high incidence rate of post surgery
complications such as retching and dizziness. It is also observed
that, after anesthesia cessation, PONV is the common cause of patient
dissatisfaction. According to the International Anesthesia Research
Society, more than 40 million undergo various surgeries annually in
the U.S. and more than 100 million patients globally with almost 30%
of the patients experiencing PONV. Studies also suggest that patients
across North America and Europe often pay more than USD 100 to avoid
postoperative complications. Thus, this huge base of patients
suffering from postoperative nausea and vomiting is likely to boost
the growth of the overall PONV treatment market. However, other
regions such as South East Asia and Africa are some of the potential
regions that are likely to grow in the near future.
The primary factors contributing to the growth of
this market are rise in incidence rate of postoperative complications
such as nausea, dizziness and vomiting along with increased numbers
of surgical procedures performed among population. Moreover,
introduction of promising drugs in this market is likely to boost the
overall postoperative nausea and vomiting treatment market due to the
high success and effectiveness rate of the potential molecules.
Furthermore, increasing government support for developing novel
therapies and personalized medicines along with high research and
development initiatives on the development of cost-effective drugs
are expected to fuel the growth of this market.
Additionally, advanced drug delivery technologies
such as microneedle arrays and biodegradable particles along with
increased focus on retaining superior quality of life are some of the
factors that might contribute to the growth of this market. However,
rise in overall healthcare expenditure, tedious regulatory approval
and product availability are some of the market-restraining factors
that might hinder the growth of the post operative nausea and
vomiting treatment market in the near future.
Currently, the postoperative nausea and vomiting
treatment market is a burgeoning and promising market venture due to
the high incidence of post surgery complications such as vomiting and
dizziness along increased number of surgical procedures. However, at
present the market is highly fragmented owing to the involvement of
many established as well as emerging players in this industry. Some
of the key market players operating in this market are Acacia Pharma
Ltd., Actavis plc, AstraZeneca plc and GlaxoSmithKline plc, amongst
others.
–
This research report analyzes this market on the basis of
its market segments, major geographies, and current market trends.
Geographies analyzed under this research report include
- North America
- Asia Pacific
- Europe
- Rest of the World
– This report provides comprehensive
analysis of
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years
This report is a
complete study of current trends in the market, industry growth
drivers, and restraints. It provides market projections for the
coming years. It includes analysis of recent developments in
technology, Porter’s five force model analysis and detailed
profiles of top industry players. The report also includes a review
of micro and macro factors essential for the existing market players
and new entrants along with detailed value chain analysis.
– Reasons for Buying this Report
- This report provides pin-point analysis for changing competitive dynamics
- It provides a forward looking perspective on different factors driving or restraining market growth
- It provides a six-year forecast assessed on the basis of how the market is predicted to grow
- It helps in understanding the key product segments and their future
- It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
- It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
- It provides distinctive graphics and exemplified SWOT analysis of major market segments
Comments
Post a Comment